Article
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2025
Feng Jamie, Hueniken Katrina, Fan Zhen Jason, Zhan Luna Jia, Faour Elizabeth, Corke Lucy, Alghabban Abdulrahman, Leighl Natasha B, Liu Geoffrey, Bradbury Penelope A, Sacher Adrian, Eng Lawson, Stockley Tracy L, Tsao Ming Sound, Shepherd Frances A
Abstract excerpt
BACKGROUND: TP53 mutations (TP53-MUT) are common in NSCLC and have been reported as predictive of response and prognostic of poor outcome in EGFR-mutant NSCLC. The impact of TP53-MUT in NSCLCs with rarer driver mutations and approved targeted treatments is unclear. METHODS: Records of 436 patients were reviewed and associations between TP53 status, demographics, and outcomes (overall response [ORR], survival [OS]...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Male
- Female
